BH4 deficiency

The Pharmaceutical Benefits Scheme (PBS) subsidises sapropterin for patients with tetrahydrobiopterin (BH4) deficiency.

Patient eligibility

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing BH4 deficiencysapropterin. Patients must meet the relevant criteria as indicated in the restrictions and be eligible for the Pharmaceutical Benefits Scheme.


From 1 February 2020, treatment with sapropterin is Authority Required (Telephone).

You can either request authority approval using Online PBS Authorities in HPOS, or call the PBS authority approvals enquiry line.

More information

For more information contact us on the PBS Authority Approvals Enquiry line.

Page last updated: 23 March 2023.